NCT06668935 - Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring | Biotech Hunter

Enrollment

800

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2027

Conditions

Diabetes Mellitus

Interventions

DEVICE

To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists

All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.

Trial Locations (2)

32216

RECRUITING

East Coast Institute for Research, LLC, Jacksonville

33169

RECRUITING

Excellence Medical and Research, Miami Gardens